Neuralina Therapeutics

Neuralina Therapeutics is a biopharmaceutical company focused on developing anti-dyskinetic therapies for patients with Parkinson’s disease. The company utilizes a strategy that involves identifying and repurposing FDA-approved drugs that have demonstrated efficacy in validated preclinical models of Parkinson’s disease. By leveraging molecules with established safety and tolerability profiles, the company aims to create a more efficient, shorter pathway-to-market for effective treatment options.

The development of these therapeutics is designed to address the unmet medical needs of Parkinson’s patients suffering from dyskinesia, which is characterized by involuntary muscular movements. Neuralina Therapeutics is currently active in the drug development pipeline for this condition, working to optimize treatment outcomes in conjunction with L-DOPA therapy. The company's efforts are centered on translational research and preclinical validation to provide patients with rapid access to therapeutic alternatives that manage the symptoms associated with neurodegenerative disease.